Quantification of treatment effect modification on both an additive and multiplicative scale

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Girerd, Nicolas ^a   Rabilloud, Muriel ^b,c,d,e   Pibarot, Philippe ^f   Mathieu, Patrick ^f   Roy, Pascal ^b,c,d,e  

^a UNIVERSITÉ DE LORRAINE   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^f UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY SURGERY; FOLLOW UP; HAZARD RATIO; HUMAN; INTERNAL MAMMARY ARTERY; PROPENSITY SCORE; QUANTITATIVE STUDY; RISK REDUCTION; AGED; CORONARY ARTERY BYPASS GRAFT; FEMALE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THEORETICAL MODEL; TREATMENT OUTCOME;

AGED; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84963679482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153010     Document Type: Article

References (37)

1. Girerd N, Rossignol P, Zannad F. Fibrinolysis for intermediate-risk pulmonary embolism. N Engl J Med. 2014;371(6):579.
2. Ferreira JP, Coiro S, Girerd N. A Systematic Assessment of Absolute Treatment Effect. Am J Cardiol. 2015;116(5):829-31. doi: 10.1016/j.amjcard.2015.07.023 PMID: 26253997
3. Coiro S, Pedro Ferreira J, Ambrosio G, Zannad F, Girerd N. To the Editor-Diabetes and sudden death: Let's assess the absolute risk increase rather than the proportional risk from sudden cardiac death! Heart Rhythm. 2015;12(11):e138.
4. Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, et al. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Eur Heart J. 2015;36(34):2310-7. doi: 10.1093/eurheartj/ehv273 PMID: 26093641
5. Girerd N, Zannad F, Rossignol P. Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients! Diabetes Metab. 2015;41(6):446-55. doi: 10.1016/j. diabet.2015.06.004 PMID: 26249760
6. Suissa D, Brassard P, Smiechowski B, Suissa S. Number needed to treat is incorrect without proper time-related considerations. J Clin Epidemiol. 2011;65(1):42-6. doi: 10.1016/j.jclinepi.2011.04.009 PMID: 21816576
7. Girerd N, Magne J, Rabilloud M, Charbonneau E, Mohamadi S, Pibarot P, et al. The impact of complete revascularization on long-term survival is strongly dependent on age. Ann Thorac Surg. 2012;94(4):1166-72. doi: 10.1016/j.athoracsur.2012.05.023 PMID: 22748638
8. Mohammadi S, Dagenais F, Doyle D, Mathieu P, Baillot R, Charbonneau E, et al. Age cut-off for the loss of benefit from bilateral internal thoracic artery grafting. Eur J Cardiothorac Surg. 2008;33(6):977-82. doi: 10.1016/j.ejcts.2008.03.026 PMID: 18448349
9. Mohammadi S, Kalavrouziotis D, Dagenais F, Voisine P, Charbonneau E. Completeness of revascularization and survival among octogenarians with triple-vessel disease. Ann Thorac Surg. 2012;93(5):1432-7. doi: 10.1016/j.athoracsur.2012.02.033 PMID: 22480392
10. Rod NH, Lange T, Andersen I, Marott JL, Diderichsen F. Additive interaction in survival analysis: use of the additive hazards model. Epidemiology. 2012;23(5):733-7. doi: 10.1097/EDE.0b013e31825fa218 PMID: 22732385
11. Nordahl H, Rod NH, Frederiksen BL, Andersen I, Lange T, Diderichsen F, et al. Education and risk of coronary heart disease: assessment of mediation by behavioral risk factors using the additive hazards model. Eur J Epidemiol. 2013;28(2):149-57. doi: 10.1007/s10654-012-9745-z PMID: 23179630
12. Giolo SR, Krieger JE, Mansur AJ, Pereira AC. Survival analysis of patients with heart failure: implications of time-varying regression effects in modeling mortality. PLoS One. 2012;7(6):e37392. doi: 10. 1371/journal.pone.0037392 PMID: 22715367
13. Abadi A, Saadat S, Yavari P, Bajdik C, Jalili P. Comparison of Aalen's additive and Cox proportional hazards models for breast cancer survival: analysis of population-based data from British Columbia, Canada. Asian Pac J Cancer Prev. 2011;12(11):3113-6. PMID: 22393999
14. Martinussen T, Scheike TH. The additive hazards model with high-dimensional regressors. Lifetime Data Anal. 2009;15(3):330-42. doi: 10.1007/s10985-009-9111-y PMID: 19184421
15. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-5. PMID: 10582940
16. Girerd N, Rabilloud M, Duarte K, Roy P. Number needed to treat from absolute risk and incidence rate: how to make apples and oranges comparable? J Clin Epidemiol. 2014;67(2):236-8. doi: 10.1016/j. jclinepi.2013.08.010 PMID: 24210846
17. Austin PC. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J Clin Epidemiol. 2010;63(1):46-55. doi: 10.1016/j.jclinepi. 2009.03.012 PMID: 19595575
18. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32(16):2837-49. doi: 10.1002/sim.5705 PMID: 23239115
19. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242-58. doi: 10.1002/sim.5984 PMID: 24122911
20. Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ. 2004;171(4):353-8. PMID: 15313996
21. Gigerenzer G, Wegwarth O, Feufel M. Misleading communication of risk. BMJ. 2010;341 (c4830. doi: 10.1136/bmj.c4830 PMID: 20940219
22. King NB, Harper S, Young ME. Use of relative and absolute effect measures in reporting health inequalities: structured review. BMJ. 2012;345 (e5774. doi: 10.1136/bmj.e5774 PMID: 22945952
23. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340 (c332. doi: 10.1136/bmj.c332 PMID: 20332509
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-9. doi: 10.1016/j.jclinepi.2007.11.008 PMID: 18313558
25. Knol MJ, van der Tweel I, Grobbee DE, Numans ME, Geerlings MI. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol. 2007;36(5):1111-8. PMID: 17726040
26. Knol MJ, Vander Weele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41(2):514-20. doi: 10.1093/ije/dyr218 PMID: 22253321
27. Venekamp RP, Rovers MM, Hoes AW, Knol MJ. Subgroup analysis in randomized controlled trials appeared to be dependent on whether relative or absolute effect measures were used. J Clin Epidemiol. 2014;67(4):410-5. doi: 10.1016/j.jclinepi.2013.11.003 PMID: 24508145
28. Gram IT, Sandin S, Braaten T, Lund E, Weiderpass E. The hazards of death by smoking in middleaged women. Eur J Epidemiol. 2013;28(10):799-806. PMID: 24078008
29. Blix K, Braekkan SK, le Cessie S, Skjeldestad FE, Cannegieter SC, Hansen JB. The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromso study. Eur J Epidemiol. 2014;29(4):277-84. doi: 10.1007/s10654-014-9902-7 PMID: 24748425
30. Knol MJ, Vander Weele TJ. Recoding preventive exposures to get valid measures of interaction on an additive scale. Eur J Epidemiol. 2011;26(10):825-6; author reply 26. doi: 10.1007/s10654-011-9613-2 PMID: 21892791
31. Knol MJ, Vander Weele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol. 2011;26(6):433-8. doi: 10.1007/s10654-011-9554-9 PMID: 21344323
32. Coughlin SS, Nass CC, Pickle LW, Trock B, Bunin G. Regression methods for estimating attributable risk in population-based case-control studies: a comparison of additive and multiplicative models. Am J Epidemiol. 1991;133(3):305-13. PMID: 2000848
33. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17(17):1923-42. PMID: 9777687
34. Spencer FA, Iorio A, You J, Murad MH, Schunemann HJ, Vandvik PO, et al. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ. 2012;345 (e7401. doi: 10.1136/bmj.e7401 PMID: 23152569
35. Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ. 2013;346 (e5793. doi: 10.1136/bmj. e5793 PMID: 23386361
36. Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ. 2012;344 (e4178. doi: 10.1136/bmj.e4178 PMID: 22730543
37. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ. 2006;333(7581):1248. PMID: 17060338